FDA adds a boxed warning to ferric carboxymaltose prescribing information, emphasizing severe low phosphate risks and mandatory monitoring protocols.

Significant improvement seen in self-reported brain fog, concentration, working memory, processing speed, verbal memory, problem solving.

The phase 3 REMODEL-1/-2 trials demonstrated the superiority of remibrutinib vs teriflunomide in reducing annualized relapse rate in RMS patients.

HealthDay News — Unintentional ingestion of recreational drugs increased substantially in US children younger than 6 years of age from 2000 to 2024, according to a study published online June 24 in ...

HealthDay News — Lower adherence to blood pressure-lowering medication is associated with no benefit for preventing cardiovascular events, according to a study presented at the annual meeting of the ...

Phase 3 SURPASS-ET data support the expanded indication of ropeginterferon alfa-2b-njft as the first new FDA-approved essential thrombocythemia therapy in nearly 3 decades.

Approval of the IL-12/23 antagonist in pediatric ulcerative colitis was supported by data from the phase 3 UNIFI Jr trial, demonstrating 52-week clinical remission and favorable tolerability.

Effective atrial fibrillation management requires rate or rhythm control, anticoagulation based on risk scores, and lifestyle ...

Mimrylo is the first subcutaneous hepcidin mimetic approved to control hematocrit levels and reduce phlebotomy burden in patients with polycythemia vera.

A healthy lifestyle in early childhood is associated with a reduced risk for inflammatory bowel disease (IBD), according to a study published online August 24 i ...

The researchers found that the adjusted mean percentage change in body weight at the 24-month follow-up was −3.40% for the Mediterranean-style intervention and −3.51% for the control intervention. The ...

FDA approves updated 2026-2027 COVID-19 vaccine formulations targeting the XFG variant for older adults and high-risk ...